Cargando…

Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

BACKGROUND: Atopic dermatitis (AD) is a complex, chronic, inflammatory skin disease characterized by pruritic, intense itching, and eczematous lesions affecting about 25% of children and 2% to 3% of adults worldwide. Abrocitinib is a selective inhibitor of Janus kinase-1 (JAK1) enzyme inhibiting the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fadlalmola, Hammad Ali, Albadrani, Muayad Saud, Elhusein, Amal Mohamed, Mohamedsalih, Wahieba E., Swamy, Veerabhadra D. S., Mamanao, Daniel Mon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245258/
https://www.ncbi.nlm.nih.gov/pubmed/34257642
http://dx.doi.org/10.1155/2021/8382761
_version_ 1783716080037920768
author Fadlalmola, Hammad Ali
Albadrani, Muayad Saud
Elhusein, Amal Mohamed
Mohamedsalih, Wahieba E.
Swamy, Veerabhadra D. S.
Mamanao, Daniel Mon
author_facet Fadlalmola, Hammad Ali
Albadrani, Muayad Saud
Elhusein, Amal Mohamed
Mohamedsalih, Wahieba E.
Swamy, Veerabhadra D. S.
Mamanao, Daniel Mon
author_sort Fadlalmola, Hammad Ali
collection PubMed
description BACKGROUND: Atopic dermatitis (AD) is a complex, chronic, inflammatory skin disease characterized by pruritic, intense itching, and eczematous lesions affecting about 25% of children and 2% to 3% of adults worldwide. Abrocitinib is a selective inhibitor of Janus kinase-1 (JAK1) enzyme inhibiting the inflammatory process. Therefore, we aimed to assess the efficacy and safety of abrocitinib for moderate-to-severe AD. METHODS: We systematically searched PubMed, Cochrane, Web of Science, Scopus, and EczemATrials till Feb 1, 2021, for reliable trials. The analysis was conducted using an inverse-variance method. The results were pooled as mean difference/event rate and 95% confidence interval. RESULTS: Abrocitinib 100 mg and 200 mg were associated with higher IGA response, EASI-50% responders, EASI-75% responders, EASI-90% responders, number of participants with at least 4-point improvements in NRS, and quality of life measured by DLQI and CDLQI than placebo. Also, 100 mg and 200 mg were associated with lower SCORAD index, %BSA, PSAAD index, and POEM index than placebo. Abrocitinib 100 mg and 200 mg were not associated with adverse events such as upper respiratory tract infection, nasopharyngitis, dermatitis, atopic, any serious adverse events, and death. CONCLUSION: Abrocitinib in dose 100 mg or 200 mg is an effective, well-tolerated, and promising drug in treating patients with moderate-to-severe atopic dermatitis. However, the analysis favored the efficacy of abrocitinib 200 mg over 100 mg, but side effects such as nausea and headache are likely to occur more with 200 mg.
format Online
Article
Text
id pubmed-8245258
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-82452582021-07-12 Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials Fadlalmola, Hammad Ali Albadrani, Muayad Saud Elhusein, Amal Mohamed Mohamedsalih, Wahieba E. Swamy, Veerabhadra D. S. Mamanao, Daniel Mon Dermatol Res Pract Review Article BACKGROUND: Atopic dermatitis (AD) is a complex, chronic, inflammatory skin disease characterized by pruritic, intense itching, and eczematous lesions affecting about 25% of children and 2% to 3% of adults worldwide. Abrocitinib is a selective inhibitor of Janus kinase-1 (JAK1) enzyme inhibiting the inflammatory process. Therefore, we aimed to assess the efficacy and safety of abrocitinib for moderate-to-severe AD. METHODS: We systematically searched PubMed, Cochrane, Web of Science, Scopus, and EczemATrials till Feb 1, 2021, for reliable trials. The analysis was conducted using an inverse-variance method. The results were pooled as mean difference/event rate and 95% confidence interval. RESULTS: Abrocitinib 100 mg and 200 mg were associated with higher IGA response, EASI-50% responders, EASI-75% responders, EASI-90% responders, number of participants with at least 4-point improvements in NRS, and quality of life measured by DLQI and CDLQI than placebo. Also, 100 mg and 200 mg were associated with lower SCORAD index, %BSA, PSAAD index, and POEM index than placebo. Abrocitinib 100 mg and 200 mg were not associated with adverse events such as upper respiratory tract infection, nasopharyngitis, dermatitis, atopic, any serious adverse events, and death. CONCLUSION: Abrocitinib in dose 100 mg or 200 mg is an effective, well-tolerated, and promising drug in treating patients with moderate-to-severe atopic dermatitis. However, the analysis favored the efficacy of abrocitinib 200 mg over 100 mg, but side effects such as nausea and headache are likely to occur more with 200 mg. Hindawi 2021-06-22 /pmc/articles/PMC8245258/ /pubmed/34257642 http://dx.doi.org/10.1155/2021/8382761 Text en Copyright © 2021 Hammad Ali Fadlalmola et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Fadlalmola, Hammad Ali
Albadrani, Muayad Saud
Elhusein, Amal Mohamed
Mohamedsalih, Wahieba E.
Swamy, Veerabhadra D. S.
Mamanao, Daniel Mon
Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
title Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
title_full Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
title_fullStr Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
title_full_unstemmed Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
title_short Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
title_sort effectiveness and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a systematic review and meta-analysis of randomized clinical trials
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245258/
https://www.ncbi.nlm.nih.gov/pubmed/34257642
http://dx.doi.org/10.1155/2021/8382761
work_keys_str_mv AT fadlalmolahammadali effectivenessandsafetyofabrocitinibinpatientswithmoderatetosevereatopicdermatitisasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT albadranimuayadsaud effectivenessandsafetyofabrocitinibinpatientswithmoderatetosevereatopicdermatitisasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT elhuseinamalmohamed effectivenessandsafetyofabrocitinibinpatientswithmoderatetosevereatopicdermatitisasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT mohamedsalihwahiebae effectivenessandsafetyofabrocitinibinpatientswithmoderatetosevereatopicdermatitisasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT swamyveerabhadrads effectivenessandsafetyofabrocitinibinpatientswithmoderatetosevereatopicdermatitisasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT mamanaodanielmon effectivenessandsafetyofabrocitinibinpatientswithmoderatetosevereatopicdermatitisasystematicreviewandmetaanalysisofrandomizedclinicaltrials